Professor of Pediatrics
Northwell Health and Cohen's Children's Medical Center, New Hyde Park, NY
Zucker SOM at Hofstra/Northwell
New Hyde Park, New York, United States
Dr. Banu Aygun, Associate Director of Hematology and Section Head of Sickle Cell Disease at Cohen Children's Medical Center in NY has treated children with sickle cell anemia for more than two decades. She has participated in several NHLBI-funded multicenter trials for sickle cell anemia including SWiTCH (Stroke with Transfusions Changing to Hydroxyurea), TWiTCH (TCD with Transfusions Changing to Hydroxyurea) and SCATE (Sparing Conversion to Abnormal TCD Elevation). Currently she is the hydroxyurea consultant for the NHLBI-funded Realizing Effectiveness Across Continents with Hydroxyurea (REACH) study. She is also the site investigator for PCORI-funded Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS), NINR-funded Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) and bluebird bio funded HBG-206 gene therapy study in sickle cell disease. She has a grant from New York State for coordinating care and supporting transition for children, adolescents and young adults with sickle cell disease. She is a member of the ASH sickle cell disease clinical trials network taskforce.
Disclosure information not submitted.
Lovotibeglogene Autotemcel Gene Therapy For Sickle Cell Disease: 60 Months Follow-Up
Saturday, June 8, 2024
8:45 AM – 9:00 AM ET